Chemical Mediators and the Resolution of Airway Inflammation

Busse, 1995 Masoli, 2003 Serra-Batlles, 1998, Costs of asthma according to the degree of severity, Eur Respir J, 12, 1322, 10.1183/09031936.98.12061322 Serhan, 1984, Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes, Proc Natl Acad Sci U S A, 81, 5335, 10.1073/pnas.81.17.5335 Serhan, 2008, Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators, Nat Rev Immunol, 8, 349, 10.1038/nri2294 Claria, 1995, Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions, Proc Natl Acad Sci U S A, 92, 9475, 10.1073/pnas.92.21.9475 Fiore, 1994, Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor, J Exp Med, 180, 253, 10.1084/jem.180.1.253 Bonnans, 2006, Lipoxin A (4)regulates bronchial epithelial cell responses to acid injury, Am J Pathol, 168, 1064, 10.2353/ajpath.2006.051056 Gronert, 1998, Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin(IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release, J Exp Med, 187, 1285, 10.1084/jem.187.8.1285 Maddox, 1997, Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor, J Biol Chem, 272, 6972, 10.1074/jbc.272.11.6972 Sodin-Semrl, 2000, Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases, J Immunol, 164, 2660, 10.4049/jimmunol.164.5.2660 Levy, 2002, Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4), Nat Med, 8, 1018, 10.1038/nm748 Hayhoe, 2006, Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement, Blood, 107, 2123, 10.1182/blood-2005-08-3099 Perretti, 2002, Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor, Nat Med, 8, 1296, 10.1038/nm786 Goulding, 1990, Hydrocortisone induces lipocortin 1 production by peripheral blood mononuclear cells in vivo in man, Biochem Soc Trans, 18, 306, 10.1042/bst0180306 Gronert, 2001, Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4)receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses, Am J Pathol, 158, 3, 10.1016/S0002-9440(10)63937-5 Schaldach, 1999, Lipoxin A4: a new class of ligand for the Ah receptor, Biochemistry, 38, 7594, 10.1021/bi982861e Serhan, 2002, Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution, Prostaglandins Other Lipid Mediat, 68–69, 433, 10.1016/S0090-6980(02)00047-3 Celik, 2007, Lipoxin A4 levels in asthma: relation with disease severity and aspirin sensitivity, Clin Exp Allergy, 37, 1494 Vachier, 2005, Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound, J Allergy Clin Immunol, 115, 55, 10.1016/j.jaci.2004.09.038 Levy, 2005, Diminished lipoxin biosynthesis in severe asthma, Am J Respir Crit Care Med, 172, 824, 10.1164/rccm.200410-1413OC Colgan, 1993, Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers, J Clin Invest, 92, 75, 10.1172/JCI116601 Levy, 1999, Polyisoprenyl phosphate (PIPP) signaling regulates phospholipase D activity: a ‘stop’ signaling switch for aspirin-triggered lipoxin A4, FASEB J, 13, 903, 10.1096/fasebj.13.8.903 Serhan, 1995, Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils, Biochemistry, 34, 14609, 10.1021/bi00044a041 Gewirtz, 1999, LXA4, aspirin-triggered 15-epi-LXA4, and their analogs selectively downregulate PMN azurophilic degranulation, Am J Physiol, 276, C988, 10.1152/ajpcell.1999.276.4.C988 Maddox, 1996, Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction, J Exp Med, 183, 137, 10.1084/jem.183.1.137 Godson, 2000, Cutting edge: lipoxins rapidly stimulate non-phlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages, J Immunol, 164, 1663, 10.4049/jimmunol.164.4.1663 Canny, 2002, Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia.[see comment], Proc Natl Acad Sci U S A, 99, 3902, 10.1073/pnas.052533799 Levy, 1997, Polyisoprenyl phosphates in intracellular signalling, Nature, 389, 985, 10.1038/40180 Levy, 2000, Polyisoprenyl phosphate signaling: topography in human neutrophils, Biochem Biophys Res Commun, 275, 739, 10.1006/bbrc.2000.3371 Hawkins, 2007, The role of PI3Ks in the regulation of the neutrophil NADPH oxidase, Biochem Soc Symp, 74, 59, 10.1042/BSS0740059 Gomez-Cambronero, 1998, Phospholipase D: a novel major player in signal transduction, Cell Signal, 10, 387, 10.1016/S0898-6568(97)00197-6 Bonnans, 2006, Regulation of phosphatidylinositol 3-kinase by poly-isoprenyl phosphates in neutrophil-mediated tissue injury, J Exp Med, 203, 857, 10.1084/jem.20052143 Levy, 2005, Novel polyisoprenyl phosphates block phospholipase D and human neutrophil activation in vitro and murine peritoneal inflammation in vivo, Br J Pharmacol, 146, 344, 10.1038/sj.bjp.0706338 Fukunaga, 2006, Identification and functional characterization of a presqualene diphosphate phosphatase, J Biol Chem, 281, 9490, 10.1074/jbc.M512970200 Sigal, 2005, Integral membrane lipid phosphatases/phosphotransferases: common structure and diverse functions, Biochem J, 387, 281, 10.1042/BJ20041771 Olsen, 2006, Global, in vivo, and site-specific phosphorylation dynamics in signaling networks, Cell, 127, 635, 10.1016/j.cell.2006.09.026 McKay, 2004, A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma, J Immunol, 172, 2903, 10.4049/jimmunol.172.5.2903 Serhan, 2000, Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing, J Exp Med, 192, 1197, 10.1084/jem.192.8.1197 Serhan, 2002, Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals, J Exp Med, 196, 1025, 10.1084/jem.20020760 Tjonahen, 2006, Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis.[see comment], Chem Biol, 13, 1193, 10.1016/j.chembiol.2006.09.011 Arita, 2005, Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1, J Exp Med, 201, 713, 10.1084/jem.20042031 Wittamer, 2003, Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids, J Exp Med, 198, 977, 10.1084/jem.20030382 Cash, 2008, Synthetic chemerin-derived peptides suppress inflammation through ChemR23, J Exp Med, 205, 767, 10.1084/jem.20071601 Arita, 2007, Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation, J Immunol, 178, 3912, 10.4049/jimmunol.178.6.3912 Toda, 2002, Leukotriene B4 receptors, Prostaglandins Other Lipid Mediat, 68–69, 575, 10.1016/S0090-6980(02)00056-4 Hong, 2003, Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation, J Biol Chem, 278, 14677, 10.1074/jbc.M300218200 Serhan, 2006, Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes, J Immunol, 176, 1848, 10.4049/jimmunol.176.3.1848 Marcheselli, 2003, Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression, J Biol Chem, 278, 43807, 10.1074/jbc.M305841200 Schwab, 2007, Resolvin E1 and protectin D1 activate inflammation-resolution programmes, Nature, 447, 869, 10.1038/nature05877 Surette, 2008, The impact of a medical food containing gammalinolenic and eicosapentaenoic acids on asthma management and the quality of life of adult asthma patients, Curr Med Res Opin, 24, 559, 10.1185/030079908X273011 Singer, 2006, Benefit of an enteral diet enriched with eicosapentaenoic acid and gamma-linolenic acid in ventilated patients with acute lung injury, Crit Care Med, 34, 1033, 10.1097/01.CCM.0000206111.23629.0A Gadek, 1999, Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Enteral Nutrition in ARDS Study Group, Crit Care Med, 27, 1409, 10.1097/00003246-199908000-00001 Duffield, 2006, Resolvin D series and protectin D1 mitigate acute kidney injury, J Immunol, 177, 5902, 10.4049/jimmunol.177.9.5902 Sun, 2007, Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation, J Biol Chem, 282, 9323, 10.1074/jbc.M609212200 Aoki, 2008, Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma, Biochem Biophys Res Commun, 367, 509, 10.1016/j.bbrc.2008.01.012 Haworth, 2008 Levy, 2007, Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness, J Immunol, 178, 496, 10.4049/jimmunol.178.1.496 Chu, 2002, Expression and activation of 15-lipoxygenase pathway in severe asthma: relationship to eosinophilic phenotype and collagen deposition, Clin Exp Allergy, 32, 1558, 10.1046/j.1365-2222.2002.01477.x Christie, 1992, The effects of lipoxin A4 on airway responses in asthmatic subjects, Am Rev Respir Dis, 145, 1281, 10.1164/ajrccm/145.6.1281 Parkinson, 2006, Lipoxin and synthetic lipoxin analogs: an overview of anti-inflammatory functions and new concepts in immunomodulation, Inflamm Allergy Drug Targets, 5, 91, 10.2174/187152806776383125 O’Sullivan, 2007, Aromatic lipoxin A4 and lipoxin B4 analogues display potent biological activities, J Med Chem, 50, 5894, 10.1021/jm060270d Levy, 2007, Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism, FASEB J, 21, 3877, 10.1096/fj.07-8653com Bandeira-Melo, 2000, Cutting edge: lipoxin (LX) A4 and aspirin-triggered 15-epi-LXA4 block allergen-induced eosinophil trafficking, J Immunol, 164, 2267, 10.4049/jimmunol.164.5.2267 Soyombo, 1994, Effects of lipoxin A4 on chemotaxis and degranulation of human eosinophils stimulated by platelet-activating factor and N-formyl-L-methionyl-L-leucyl-L-phenylalanine, Allergy, 49, 230, 10.1111/j.1398-9995.1994.tb02654.x Aliberti, 2002, Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity, Nat Immunol, 3, 76, 10.1038/ni745 Arita, 2005, Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis, Proc Natl Acad Sci U S A, 102, 7671, 10.1073/pnas.0409271102 Hasturk, 2006, RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis, FASEB J, 20, 401, 10.1096/fj.05-4724fje Jozsef, 2002, Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes, Proc Natl Acad Sci U S A, 99, 13266, 10.1073/pnas.202296999 Bonnans, 2002, Lipoxins are potential endogenous antiinflammatory mediators in asthma, Am J Respir Crit Care Med, 165, 1531, 10.1164/rccm.200201-053OC